Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine.
作者信息
Mei Liyan, Gao Kaixin, He Xiaojuan, Jakobsson Per-Johan, Huang Runyue
机构信息
The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
China Academy of Chinese Medical Sciences, Beijing, China.
出版信息
Front Pharmacol. 2023 Feb 3;14:1135803. doi: 10.3389/fphar.2023.1135803. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine.社论：改善病情抗风湿药：传统医学的方法与经验教训
Front Pharmacol. 2023 Feb 3;14:1135803. doi: 10.3389/fphar.2023.1135803. eCollection 2023.
2
Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.糖尿病修正抗风湿药物：DMARDs 作为降血糖药物的作用。
Medicina (Kaunas). 2022 Apr 21;58(5):571. doi: 10.3390/medicina58050571.
3
Antirheumatic drugs in older adults and polypharmacy issues.老年人抗风湿药物与多重用药问题。
Z Gerontol Geriatr. 2022 Oct;55(6):507-512. doi: 10.1007/s00391-021-01907-6. Epub 2021 Jun 10.
4
Proposal for a new nomenclature of disease-modifying antirheumatic drugs.疾病修饰抗风湿药物新命名法建议。
Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26.
5
Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders.中药作为自身免疫性疾病中的免疫调节剂和潜在的病情改善抗风湿药物。
Curr Drug Metab. 2004 Apr;5(2):181-92. doi: 10.2174/1389200043489081.
6
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.美国类风湿关节炎患者使用生物制剂类改善病情抗风湿药物的经济负担。
Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1231-1241. doi: 10.1080/14737167.2022.2117690. Epub 2022 Sep 6.
7
Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran.在伊朗大流行的第一波和第二波期间，生物制剂和传统改善病情抗风湿药物对风湿病患者中新冠病毒感染发病率的影响。
Reumatologia. 2022;60(4):231-241. doi: 10.5114/reum.2022.119039. Epub 2022 Sep 7.
8
Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).合成、非生物性疾病修饰抗风湿药物（DMARDs）的心血管风险。
Curr Vasc Pharmacol. 2020;18(5):455-462. doi: 10.2174/1570161117666190930113837.
9
VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs.VZV 特异性 T 细胞水平在风湿性疾病患者中降低，并受到抗风湿药物的不同影响。
Arthritis Res Ther. 2018 Nov 9;20(1):252. doi: 10.1186/s13075-018-1742-5.
10
Association of Traditional Chinese Medicine Use With Adherence to Prescribed Western Rheumatic Medications Among Chinese American Patients: A Cross-Sectional Survey.中医药使用与美籍华裔患者遵医嘱使用风湿性西药的相关性：一项横断面调查。
Arthritis Care Res (Hoboken). 2020 Oct;72(10):1474-1480. doi: 10.1002/acr.24031.
引用本文的文献
1
Targeting Therapeutic Windows for Rheumatoid Arthritis Prevention.针对类风湿关节炎预防的治疗窗
Chin J Integr Med. 2024 Sep;30(9):842-851. doi: 10.1007/s11655-024-3760-2. Epub 2024 May 16.
2
Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.肠道微生物群对类风湿关节炎疾病修饰抗风湿药物治疗效果影响的研究进展。
Front Immunol. 2023 Sep 28;14:1189036. doi: 10.3389/fimmu.2023.1189036. eCollection 2023.
本文引用的文献
1
Global epidemiology of rheumatoid arthritis.类风湿关节炎的全球流行病学。
Nat Rev Rheumatol. 2022 Oct;18(10):591-602. doi: 10.1038/s41584-022-00827-y. Epub 2022 Sep 6.
2
: A Comprehensive Review of its Botany, Phytochemistry, Pharmacology and Clinical Application.: 全面综述其植物学、植物化学、药理学和临床应用。
Am J Chin Med. 2022;50(5):1219-1253. doi: 10.1142/S0192415X22500501. Epub 2022 Jun 8.
3
Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis.传统草药：类风湿关节炎的治疗潜力。
J Ethnopharmacol. 2021 Oct 28;279:114368. doi: 10.1016/j.jep.2021.114368. Epub 2021 Jun 29.
4
Rheumatoid Arthritis: Early Diagnosis and Treatment.类风湿性关节炎：早期诊断与治疗。
Med Clin North Am. 2021 Mar;105(2):355-365. doi: 10.1016/j.mcna.2020.10.006.
5
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.低剂量甲氨蝶呤的不良反应：一项随机试验。
Ann Intern Med. 2020 Mar 17;172(6):369-380. doi: 10.7326/M19-3369. Epub 2020 Feb 18.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略：2019 年更新版（使用合成和生物疾病修正抗风湿药物）
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
7
Herbal compounds for rheumatoid arthritis: Literatures review and cheminformatics prediction.草药化合物治疗类风湿性关节炎：文献综述与 cheminformatics 预测。
Phytother Res. 2020 Jan;34(1):51-66. doi: 10.1002/ptr.6509. Epub 2019 Sep 12.
8
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.多靶点导向配体的合理设计：策略和新兴范例。
J Med Chem. 2019 Oct 24;62(20):8881-8914. doi: 10.1021/acs.jmedchem.9b00017. Epub 2019 May 28.
9
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.类风湿关节炎患者使用生物制剂和合成疾病修饰抗风湿药物的心血管事件风险比较：系统评价和荟萃分析。
Arthritis Care Res (Hoboken). 2020 Apr;72(4):561-576. doi: 10.1002/acr.23875.
10
A survey of traditional Chinese medicine use among rheumatoid arthritis patients: a claims data-based cohort study.类风湿关节炎患者使用中药的调查：基于理赔数据的队列研究。
Clin Rheumatol. 2019 May;38(5):1393-1400. doi: 10.1007/s10067-018-04425-w. Epub 2019 Jan 22.
Zotero 插件